Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management

Northwell Health Ranked Nation’s Top Health System for Diversity

New York State’s largest health care provider and private employer made the list for the ninth straight year and remained in the top spot in the 2021 DiversityInc rankings for Hospitals and Health Systems.

ZAP Surgical and Swiss Neuro Radiosurgery Center Announce Imminent Installation of New Gyroscopic Radiosurgery Platform for Treating Brain Tumors

ZAP-X is also the first and only dedicated radiosurgery system to no longer require Cobalt-60 radioactive sources, thus eliminating the significant costs to license, secure and regularly replace live radioactive isotopes.

Kathy Sherwood Joins Pelvital USA, Inc. Board of Directors

Sherwood's experience, which includes a diverse group of medical product companies such as Boston Scientific, American Medical Systems, St. Jude Medical, Kinetic Concepts, Transoma Medical and Medtronic, gives her an understanding of the problems faced by both large and small companies.

Medtronic plc (NYSE:MDT), announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Personalized Closed Loop (PCL) insulin pump system, currently in development. The PCL technology is designed to automate insulin delivery in a way that is real-time, personalized and adapts to the user. The system will also provide insights and predictive diagnostics unique to the individual, with a goal of dramatically simplifying diabetes management for the patient. The recent acquisition of Nutrino Health and their expertise in nutrition data science will play a key role in the accelerated development of this breakthrough technology.

The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Under the program, the FDA will provide Medtronic with priority review and interactive communication regarding device development and clinical trial protocols, through to commercialization decisions.

“We are very excited to receive the Breakthrough Device designation from the FDA as it will help us deliver this broadly anticipated innovation to patients much sooner than expected,” said Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic. “We believe the Personalized Closed Loop system will be transformational for diabetes management, and the personalized nature of the algorithm clears the path to a true closed loop system. We have a long history of partnership with the FDA and look forward to another successful collaboration with the Agency to bring this important innovation to patients.”

“It is incredibly rewarding as an endocrinologist to see this novel closed loop innovation in development as it holds significant promise for simplifying diabetes management and taking on much more of the work on behalf of the patient,” said Dr. Kevin Kaiserman, pediatric endocrinologist, SoCal Diabetes. “I’m pleased to see the FDA continuing to support the acceleration of important therapeutic options that address true unmet needs and commend them for these efforts.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles